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Proline-rich transmembrane protein 2 (PRRT2) has been
identified as the single causative gene for a group of paroxysmal
syndromes of infancy, including epilepsy, paroxysmal move-
ment disorders, and migraine. On the basis of topology predic-
tions, PRRT2 has been assigned to the recently characterized
family of Dispanins, whose members share the two-transmem-
brane domain topology with a large N terminus and short C
terminus oriented toward the outside of the cell. Because
PRRT2 plays a role at the synapse, it is important to confirm the
exact orientation of its N and C termini with respect to the
plasma membrane to get clues regarding its possible function.
Using a combination of different experimental approaches,
including live immunolabeling, immunogold electron micros-
copy, surface biotinylation and computational modeling, we
demonstrate a novel topology for this protein. PRRT2 is a type II
transmembrane protein in which only the second hydrophobic
segment spans the plasma membrane, whereas the first one is
associated with the internal surface of the membrane and forms
a helix-loop-helix structure without crossing it. Most impor-
tantly, the large proline-rich N-terminal domain is not exposed
to the extracellular space but is localized intracellularly, and
only the short C terminus is extracellular (Ncyt/Cexo topology).
Accordingly, we show that PRRT2 interacts with the Src homo-
logy 3 domain-bearing protein Intersectin 1, an intracellular
protein involved in synaptic vesicle cycling. These findings will
contribute to the clarification of the role of PRRT2 at the syn-
apse and the understanding of pathogenic mechanisms on the
basis of PRRT2-related neurological disorders.
Proline-rich transmembrane protein 2 (PRRT2) is encoded
by a gene that has been shown recently to be the single causative
gene for a group of paroxysmal syndromes of infancy, including
benign familial infantile seizures, infantile convulsion choreo-
athetosis, migraine, hemiplegic migraine, and paroxysmal kine-
sigenic dyskinesia/choreoathetosis. A large number of PRRT2
nonsense, frameshift, and missense mutations have been asso-
ciated with diseases with a variable phenotypic spectrum, rang-
ing from mild forms that improve with age to severe pheno-
types (1–5).
The PRRT2 gene encodes for a protein highly conserved
across species, with an average of 80% similarity across mam-
mals and 30% with zebrafish. The sequence similarity increases
in the C-terminal region containing the predicted transmem-
brane domains, becoming over 90% in mammals and 60% in
zebrafish (6). On the basis of topology prediction, PRRT2 has
been assigned to the newly characterized large family of Dispa-
nins, whose members share the two-transmembrane domain
topology and include the subfamily of interferon-induced
transmembrane proteins.
The putative topology of the Dispanins has been described as
two transmembrane helices in the C-terminal region, separated
by an intracellular loop of variable length, and an often long
N-terminal region (100 amino acids) compared with a short
C-terminal region (10 amino acids) that are both oriented
toward the outside of the cell (7). A detailed analysis of the
primary structure of human PRRT2 identified the two pre-
dicted transmembrane helices in the C-terminal region of the
protein (TM1,3 amino acids 275–295; TM2, amino acids 324 –
344): a long and relatively unstructured N-terminal region
(amino acids 1–274), including a proline-rich domain (amino
acids 133–222); an intracellular loop (amino acids 296 –323)
connecting the two transmembrane helices; and a very short
C-terminal end (8). The mouse PRRT2 ortholog is virtually
identical to the human protein in the C terminus, with few
differences in the N-terminal region (6).
Many PRRT2 mutations are highly penetrant and cause trun-
cation of the protein. The most frequent mutation is a recurrent
frameshift located in an instable region of nine cytosines, caus-
ing the introduction of a stop codon seven amino acids down-
stream of insertion (c.649 – 650insC  p.Arg217Profs*7). A
variety of other nonsense or frameshift mutations are mostly
located in the long N-terminal domain of the protein, scattered
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in the proline-rich domain, and only a few involve the TM
domains or the cytoplasmic loop. The truncated mutations are
degraded by nonsense-mediated mRNA decay or by protein
degradation, as suggested by the lack of their expression in cell
lines (9 –16).
PRRT2 mRNA is expressed in the nervous system in the cor-
tex, hippocampus, basal ganglia, and cerebellum (6, 7, 9), which
are all regions putatively involved in the pathogenesis of
PRRT2-linked diseases. The function of PRRT2 is character-
ized poorly. However, a link with the machinery of neurotrans-
mitter release has been hypothesized on the basis of results of
proteomic and biochemical studies showing an interaction with
synaptosome-associated protein 25 kDa (SNAP-25) (6, 17, 18),
one of the presynaptic SNARE proteins that constitute the
fusion core complex allowing exocytosis of synaptic vesicles
(19). In addition, a high-resolution proteomics study revealed
the presence of PRRT2 among new auxiliary proteins partici-
pating in the AMPA glutamate receptor complex, with a pref-
erential association of PRRT2 with the AMPA receptor subunit
GLUA1 (20). This putative interaction has been confirmed
recently (18). In addition, the observed colocalization of exog-
enously expressed PRRT2 with synaptic markers further sug-
gests its targeting to synaptic areas (6). All of this experimental
evidence points to a functional role of PRRT2 at the synapse.
If the topology model of the Dispanin protein family, with
both the N- and C-terminal domains exposed to the external
surface of the cell, also holds true for PRRT2, it may implicate
that the long PRRT2 N-terminal domain interacts with proteins
of the extracellular matrix and/or with extracellular domains of
synaptic proteins and works as a synaptic adhesion molecule.
Several trans-synaptic interacting proteins, such as the neur-
exin-neuroligin or the cadherin-catenin complexes, integrins,
integrin ligands, and LGI1, play crucial roles in synapse forma-
tion and functioning and are causative genes of synaptopathies
such as epilepsy and/or autism (21–24).
On the contrary, if the orientation of the N terminus with
respect to the plasma membrane were different, then a com-
pletely diverse set of putative protein interactors and other
functions could be hypothesized. In this work, we found that
PRRT2 has a different topology with respect to the one pre-
dicted for the other Dispanins. Through a series of complemen-
tary experimental approaches such as live immunolabeling,
immunogold electron microscopy, surface biotinylation, and
computational modeling, we demonstrate that the large N-ter-
minal domain is not exposed to the extracellular space but that
it is cytosolic and that only the very short C terminus is extra-
cellular (Ncyt/Cexo orientation). This topology conforms to that
of type II transmembrane proteins with a very short C-terminal
anchor and leads to the conclusion that only the second C-ter-
minal hydrophobic stretch spans the plasma membrane,
whereas the first one is associated with the inner surface of the
membrane without crossing it.
Experimental Procedures
Cell Culture Procedures
COS7 cells were cultured in advanced DMEM supplemented
with 10% fetal bovine serum, 1% L-glutamine, 100 units/ml pen-
icillin, and 100 g/ml streptomycin (Life Technologies) and
maintained at 37 °C in a 5% CO2 humidified atmosphere. Cells
were transfected with Lipofectamine 2000 (Life Technologies).
Constructs
We generated three distinct HA constructs using the pKH3
plasmid (a gift from Ian Macara, Addgene plasmid 12555) (25):
HA3 tags at the N terminus of PRRT2 (HA-PRRT2), with the
PRRT2 mouse coding sequence cloned in BamH1-EcoR1 sites;
HA3 tags at the C terminus of PRRT2 (PRRT2-HA), with the
PRRT2 mouse coding sequence without a stop codon cloned in
Hind3-Sal1; and HA3 tags between the two hydrophobic trans-
membrane segments in the putative cytosolic loop of the
protein (PRRT2-loop-HA), with PRRT2 1– 894 and PRRT2
895–1041 cloned in Hind3-Sal1 and BamH1-EcoR1 sites,
respectively. For biotinylation experiments, PRRT2-HA was
used as template to obtain a mutant (PRRT2C) lacking the
C-terminal tail (PRRT2 with a stop codon after Val-344) by
site-directed mutagenesis (forward primer 5-CAT CAA CTT
AGG CGT GTA GAA GGT CGA CTC TAG AA-3) using the
QuikChange Lightning site-directed mutagenesis kit (Agilent).
To generate PRRT2 lacking the N-terminal domain
(PRRT2N), the sequence from 799 to 1039 of the mouse
cDNA was cloned by PCR in Hind3-Sal1 sites of the pkH3 plas-
mid with the following primers: forward, AGATAAGCTTATG
GGCACCCAGAAACCTCGGGAC; reverse, CACTGTCG-
ACCTTATACACGCCTAAGTTGATGACGCA. In addition,
Lys-270 was replaced with an arginine by site-directed
mutagenesis (forward primer 5-ATGGGCACCCAGAGAC-
CTCGGGACTATATC). This construct retains the HA3 at the
C terminus of PRRT2. For the GFP construct, the PRRT2
mouse coding sequence was cloned in the pEGFP-C2 plasmid
(BD Biosciences). Mouse PRRT2 fused at the C terminus with
turboGFP was purchased from Origene. All primers were pur-
chased from Eurofins Genomics (Ebersberg, Germany).
Immunocytochemistry
Primary hippocampal neurons were fixed with 4% parafor-
maldehyde in PBS (pH 7.4) and 4% sucrose. Cells were permea-
bilized with 0.1% Triton X-100 in PBS for 5 min and blocked
with 0.1% Triton X-100 and 4% fetal bovine serum in PBS for 30
min. Samples were incubated sequentially with primary anti-
bodies in blocking solution (3 h at room temperature), followed
by Alexa Fluor 488- or 594-conjugated secondary antibodies
(Invitrogen, 1:500 for 1 h at room temperature) (26). Coverslips
were mounted using Prolong Gold antifade reagent (Invitro-
gen) and DAPI for nuclear staining. Images were captured with
an Olympus BX41 epifluorescence microscope (20/0.5 and
40X/0.75 objectives, Olympus) equipped with a QIClick-F-
M-12 charge-coupled device camera (QImaging).
Live Immunolabeling
Cells transfected with the various PRRT2 constructs were
live-labeled by diluting primary antibodies (rabbit anti-PRRT2,
1:200, Sigma-Aldrich; mouse anti-HA, 1:200, Invitrogen;
mouse anti-turboGFP, 1:200, Origene; and mouse anti-GFP,
1:500, Millipore) in culture medium for 1 h at 37 °C in a 5% CO2
incubator to detect the surface epitopes, followed by incubation
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with Alexa Fluor 488 or 594 secondary antibodies for 1 h at
37 °C, and fixed. In the experiments of live-labeling with HA
antibodies, after live incubation with Alexa Fluor 488 secondary
antibodies, cells were fixed with 4% paraformaldehyde, per-
meabilized with 0.1% Triton X-100, and stained with anti-
PRRT2 antibodies, followed by Alexa Fluor 594 secondary anti-
bodies to label total PRRT2.
Western Blotting
These experiments were performed as described previously
(27). Primary antibodies were as follows: rabbit anti-PRRT2
(1:500, Sigma-Aldrich), mouse anti-actin (1:1000, Sigma-Al-
drich), mouse anti-Na/KATPase (1:1000, Millipore), and
mouse anti-dynamin I (1:1000, Millipore).
Surface Biotinylation Assays
COS7 cells were transfected with PRRT2-HA-, PRRT2C-,
or PRRT2N-expressing plasmids. The biotinylation assay was
performed as described previously (28).
Electron Microscopy
Pre-embedding Immunogold Technique—COS7 cells were
transiently transfected with DNA encoding either HA-PRRT2
or PRRT2-HA. Pre-embedding immunogold labeling was per-
formed 48 h after transfection. Cells were fixed in 4% parafor-
maldehyde in 0.1 M PBS (pH 7.4), permeabilized and incubated
with rabbit anti-HA (1:100, Bethyl Laboratories). Samples were
then incubated with a secondary antibody (goat anti-rabbit,
1:100, Nanoprobes) conjugated to a colloidal nanogold particle
(10 nm). Cells were then fixed for 1 h in 1.2% glutaraldehyde in
PBS, post-fixed in 1% osmium tetroxide in 0.1 M sodium caco-
dylate (pH 7.4), en block stained in 0.5% uranyl acetate, dehy-
drated in a graded series of ethanol, and finally embedded in
Epon resin. Ultrathin (60- to 70-nm-thick) sections, obtained
with a Leica EM UC6 ultramicrotome, were collected on 200
mesh copper grids. The grids were observed in a Jeol JEM 1011
electron microscope operating at 100 kV and recorded with a
4-megapixel Gatan Orius SC100 charge-coupled device cam-
era. To test for specificity of the immunocytochemical proce-
dures, the HA antibody was omitted, or, alternatively, cells were
transfected with an empty vector. Under either condition, no
immunoreactivity was observed.
Post-embedding Immunogold Technique—Post-embedding
immunogold labeling was performed 48 h after transfection.
COS7 cells were detached from the Petri dish and spun at 1500
rpm. The pellet was fixed with 2% paraformaldehyde and 0.2%
glutaraldehyde in 0.1 M phosphate buffer (pH 7.4), stained with
0.5% uranyl acetate, dehydrated, and finally embedded in Low-
icryl HM20 under UV light for 2 days. Ultrathin sections (60- to
70-nm thick) were collected on formvar-coated nickel grids.
Then post-embedding immunolabeling was performed. Briefly,
sections were washed with 0.1% sodium borohydride and 50
mM glycine and incubated with the primary antibody. The sam-
ples were subsequently washed with TBS/0.1% Triton X-100
and incubated with goat anti-rabbit IgG coupled to 10-nm gold
particles diluted 1:100. Sections were then post-fixed in glutar-
aldehyde in TBS, washed with distilled water, and finally
stained with uranyl acetate and lead citrate. The grids were
observed in a Jeol JEM 1011 electron microscope as described
above.
Cryo-immunogold Technique—COS7 cells were transiently
co-transfected with both GFP-PRRT2 and PRRT2-HA and
embedded in 2% gelatin in 0.1 M phosphate buffer. Ultrathin
40-nm sections were obtained with a Leica EM UC6 ultrami-
crotome using the Tokuyasu technique (29 –30) and collected
on formvar-coated nickel grids. Sections were then incubated
with mouse anti-GFP (1:100, Millipore) and rabbit anti-HA
(1:100, Bethyl Laboratories) primary antibodies. Samples were
then incubated with goat anti-mouse and goat anti-rabbit sec-
ondary antibodies (1:100, Nanoprobes) conjugated to colloidal
nanogold particles of 10 nm (GFP labeling) and 6 nm (HA label-
ing), respectively. The grids were observed in a Jeol JEM 1011
electron microscope as described above.
SH3 Affinity Chromatography
These experiments were performed as described previously
(27, 31–33). The eluted proteins were separated by 12% SDS-
PAGE and analyzed by immunoblotting with anti-PRRT2 and
anti-dynamin I antibodies.
Co-immunoprecipitation Assays
For immunoprecipitation, 10 g of mouse anti-Intersectin 1
antibodies (clone 29, BD Biosciences), goat anti-Endophilin 1
antibodies (catalog no. sc-10874, Santa Cruz Biotechnology), or
mouse/goat control IgGs (Sigma-Aldrich) were precoated with
protein G Sepharose (GE Healthcare) overnight and incubated
with total mouse brain lysate in immunoprecipitation buffer
(150 mM NaCl, 50 mM Tris-HCl (pH 7.4), 2 mM EDTA, and 1%
Triton X-100). After extensive washes in immunoprecipitation
buffer and detergent-free immunoprecipitation buffer, samples
were resolved by SDS-PAGE and subjected to Western blotting
with anti-PRRT2 antibodies.
Structure Modeling
We used the Robetta web server (34) to model the structure
of the PRRT2 transmembrane domain, providing as input
sequence residues Gly-261 to Lys-340. Robetta implements
parts of the Rosetta structure prediction software suite (35) to
generate models of protein domains by automatically com-
bining template-based homology modeling and de novo
approaches. It first screens the sequence using BLAST, PSI-
BLAST, and 3D-Jury for regions that possess a homolog with an
experimentally determined structure and then parses the
sequence into putative domains on the basis of matches to both
known and predicted structures. Any remaining region is cut
up into small sizes and modeled via the Rosetta de novo proto-
col. On the basis of a coarse-grained energy function, the low-
est-energy models are selected and combined into a final full-
length model by optimizing the interactions between domains.
The best-scoring PRRT2 model showed good values for stan-
dard quality assessment parameters, normalized Qmean 0.49
and Z-score 1.85. Note that the average score of high-resolu-
tion x-ray structures is around 0 and that membrane proteins
usually receive lower Z scores than soluble proteins (36).
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Molecular dynamics (MD) simulations were performed
using NAMD2.9 (37) with the CHARMM27 force field for pro-
teins (with cross-term energy map corrections), ions, and water
and the CHARMM36 force field for lipids (38). The protein
transmembrane domain (Gly-261 to Lys-340 of the human
PRRT2 sequence, which is identical to the mouse sequence Gly-
267 to Lys-346) was inserted into a pre-equilibrated 1-palmi-
toyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) lipid
bilayer and solvated with water molecules and counterions to
neutralize the total system charge. The total number of atoms
in the system was about 63,000. Periodic boundary conditions
were applied, and the particle mesh Ewald method was used for
long-range electrostatics (39), with a grid spacing of 1 Å and
sixth-order B-splines. A cutoff of 12 Å and smooth switching at
10 Å was used for Lennard-Jones interactions. Chemical bond
distances involving hydrogen atoms were constrained using the
SHAKE/RATTLE algorithm (40). The full system was energy
minimized for 2000 steps, and then its temperature was
increased up to 300 K over 1.2-ns MD simulation by a sequence
of 100-ps-long simulations at constant pressure (1 atm) and
temperature, increased by 25 K at each stage. The system was
equilibrated by running 1-ns NPT simulation with p 	 1 atm
and T 	 310 K with the Langevin piston Nosé-Hoover method
(41). The simulation ensemble was then switched to a constant
volume and temperature (NVT) by keeping the temperature
stationary around 310 K via Langevin dynamics with a damping
coefficient 5 ps1 and time step of 1 fs. Two independent sim-
ulations lasting 20 and 50 ns were generated using this protocol.
Statistical Analysis
Data are expressed as mean 
 S.E. throughout. To compare
two normally distributed sample groups, two-tailed Student’s t
test was used. In the case of more than two normally distributed
experimental groups, one-way analysis of variance followed by
multiple comparison tests was employed. The significance level
was preset to p  0.05. Data were analyzed using the Prism 6.0
and SigmaPlot 10.0 softwares.
Results
Live Labeling Defines a Novel Membrane Topology for
PRRT2—The predicted membrane topology of the Dispanin
family consists of two transmembrane domains connected by a
short intracellular loop with both the N-terminal and C-termi-
nal domains oriented toward the outside of the cell. To verify
whether PRRT2 shares this topology, we generated three dis-
tinct constructs bearing a triplet of HA tags alternatively at the
N terminus (HA-PRRT2), at the C terminus (PRRT2-HA), or
within the loop connecting the two putative transmembrane
segments of PRRT2 (PRRT2-loop-HA).
When cells transfected with the various PRRT2 constructs
were permeabilized and labeled with anti-HA antibodies, all
three HA isoforms were detected with comparable expression
levels (Fig. 1A, top panels). Anti-PRRT2 antibodies, directed to
an N-terminal epitope of PRRT2, also recognized the three iso-
forms to the same extent (Fig. 1A, center panels) and, as
expected, the labeling pattern overlapped completely with the
HA staining (Fig. 1A, bottom panels). In contrast, when cells
were live-labeled, maintaining the integrity of the plasma mem-
brane, HA antibodies exclusively recognized the PRRT2-HA
isoform, confirming exposure of the C terminus of PRRT2 to
the extracellular surface. Moreover, no signal could be detected
in live cells transfected with PRRT2-loop-HA, confirming that
this putative cytosolic domain is indeed intracellular. Strik-
ingly, HA antibodies did not recognize any exposure of HA-
PRRT2 to the extracellular environment, indicating that the
long N-terminal domain of PRRT2 is not exposed on the outer
surface of the cell but, rather, is intracellular (Fig. 1B, top pan-
els). After permeabilization, PRRT2 labeling was clearly visible
to the same extent in cells transfected with any of the three
constructs (Fig. 1B, center panels), showing that the three con-
structs had a similar transfection efficiency and that the HA3
tag fused to the C terminus did not affect the membrane inser-
tion of PRRT2. PRRT2 staining overlapped with live HA label-
ing only in cells transfected with PRRT2-HA (Fig. 1B, bottom
panels). These results suggest a new topology for PRRT2, as
schematized in Fig. 1C.
Additional evidence of this novel topology of PRRT2 was
obtained by transfecting COS7 cells with a plasmid encoding
for PRRT2 fused at the C-terminal with a distinct fluorescent
tag, turbo-GFP (PRRT2-tGFP), and analyzing the cells with a
combination of anti-PRRT2 and anti-tGFP antibodies under
both permeabilizing and non-permeabilizing conditions. The
PRRT2-tGFP chimera was well expressed in cells, as shown by
the intrinsic tGFP fluorescence (Fig. 2, A and B). When cells
were permeabilized, both anti-PRRT2 antibodies (recognizing
the sequence 152–268 in the N terminus of the protein) and
anti-tGFP antibodies detected the PRRT2-tGFP fusion protein
(Fig. 2A, red signals). However, under live labeling conditions,
only the tGFP antibodies detected the C-terminal tGFP, and no
signal was detected by anti-PRRT2 antibodies, further confirm-
ing, with distinct constructs and combination of antibodies,
that the N-terminal epitopes are not accessible when the
plasma membrane is intact in the absence of detergents and
fixatives (Fig. 2B, red signal). The different accessibility of
PRRT2 epitopes to the antibodies used is schematized in the left
panels of Fig. 2. Taken together, these results suggest a topology
for the PRRT2 protein that is clearly distinct from that pre-
dicted on the basis of homology with the Dispanin family and
consistent with a type II transmembrane protein characterized
by an Ncyt/Cexo orientation, whereby only the second hydro-
phobic segment spans the plasma membrane, the first hydro-
phobic segment is associated putatively with the interior of the
plasma membrane, and the N terminus of the protein is intra-
cellular (Fig. 1C).
Immunogold Labeling Visualizes the C-terminal and N-ter-
minal Domains of PRRT2 on Opposite Sides of the Plasma
Membrane—To analyze the localization of the N-terminal and
C-terminal domains of PRRT2 in more detail, ultrathin sections
(60 –70 nm thick) of COS7 cells transfected with either HA-
PRRT2 or PRRT2-HA constructs were immunogold-labeled
for the HA tag and analyzed by electron microscopy using both
pre-embedding and post-embedding techniques. With both
techniques, when cells were transfected with C-terminally
tagged PRRT2-HA and incubated with the primary anti-HA
antibodies, gold particles were localized specifically to the
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FIGURE 1. Different localization of HA epitopes tagging the N and C termini of PRRT2 with respect to the plasma membrane. A, COS7 cells were
transfected with distinct HA-tagged PRRT2 constructs (HA-PRRT2, with HA3 tags at the N terminus; PRRT2-loop-HA, with HA3 tags between the two hydro-
phobic segments in the predicted cytosolic domain; and PRRT2-HA, with HA3 tags at the C terminus), fixed, and permeabilized for standard immunofluores-
cence. After permeabilization, both anti-HA (top panels) and anti-PRRT2 (center panels) antibodies recognized the overexpressed protein to the same extent
(Merge, bottom panels). Cell nuclei were counterstained with DAPI (blue). B, live labeling with anti-HA antibodies only recognized PRRT2-HA, and no signal was
detected in cells transfected with PRRT2-loop-HA or HA-PRRT2, indicating that the HA epitopes of these constructs were not accessible on the external surface
of the cells (top panels). The different HA constructs were expressed equally, as shown by immunostaining with anti PRRT2 antibodies obtained after permea-
bilization of the cells (center panels). Bottom panels, merged images from the top and center panels. Scale bar 	 20 m. C, schematic of the membrane topology
of PRRT2. The orientation of the N and C termini of PRRT2 with respect to the plasma membrane is shown, with the position of the HA3 tags in the protein
sequence of the three constructs used to determine the topology of the protein.
A Novel Topology for PRRT2 Supports Intracellular Functions
MARCH 18, 2016 • VOLUME 291 • NUMBER 12 JOURNAL OF BIOLOGICAL CHEMISTRY 6115
 at B












extracellular side of the plasma membrane (Fig. 3A1, A4 and B1,
B4, top panels). In contrast, when cells were transfected with
the N-terminally tagged HA-PRRT2, gold particles were only
present on the cytosolic side of the plasma membrane, consis-
tent with an intracellular location of the N terminus of the pro-
tein (Fig. 3, A2, A4 and B2, B4, bottom panels). The topography
of the immunogold particles with respect to the plasma mem-
brane is shown schematically in the ImageJ masks of the
immuno-EM images (Fig. 3, A1b, A2b and B1b, B2b). When the
primary anti-HA antibody was omitted or the cells were not
transfected with the PRRT2 constructs, no immunoreactivity
was observed (Fig. 3, A3 and B3), confirming the specificity of
the immunolabeling. Quantification of the immunolabeling
obtained with both techniques showed that the C terminus was
almost entirely located extracellularly, whereas the vast major-
ity of the staining for the N terminus was cytosolic (Fig. 3D). In
some sections, few gold particles were visualized inside the cell
with both N-terminal and C-terminal domain staining of
PRRT2. These intracellular pools presumably reflect PRRT2
trafficking in the biosynthetic and secretory pathways.
To further confirm the above data and obtain detailed map-
ping of PRRT2 across the internal membranes, such as those of
the endoplasmic reticulum, that were not well preserved using
the pre- and post-embedding techniques, we used the cryo-dual
immunogold technique in cells co-expressing both N-terminal
GFP and C-terminal HA tags. Cryosections were labeled with
anti-GFP antibodies coupled to 10-nm nanogold particles and
anti-HA antibodies coupled to 6-nm gold particles (Fig. 3C).
The data of the dual labeling fully confirmed our previous
results, showing the localization of the C terminus of PRRT2
both outside the plasma membrane and inside the intracellular
organelles, whereas the localization of the N terminus was cyto-
solic (Fig. 3E).
PRRT2 Is Surface-biotinylated at the C-terminal Domain—
To get additional evidence supporting the new emerging topol-
ogy of PRRT2, we performed protein surface biotinylation
experiments, a useful method to identify the extracellular
domains of membrane proteins. When the primary structure of
mouse PRRT2 was analyzed, of the 12 lysines representing the
preferential biotinylation sites, 10 were present in the N-termi-
nal domain, one in the intracellular loop (Lys-320), and one in
the C-terminal domain as the last amino acid of the protein
sequence (Lys-346). If the novel PRRT2 topology suggested by
the above-described results were true, then the C-terminal
lysine would be the only residue accessible to extracellular bio-
tin labeling, whereas the multiple N-terminal lysines would be
intracellular and could not bind biotin. To demonstrate the
crucial role of the C-terminal lysine in biotinylation experi-
FIGURE 2. Tagging PRRT2 with an alternative fluorescent epitope confirms the opposite location of the N and C termini with respect to the plasma
membrane. A, COS7 cells were transfected with a plasmid encoding for PRRT2 with C-terminal tGFP. After permeabilization, both anti-PRRT2 antibodies
recognizing the N terminus (sequence 152–268) and anti-tGFP antibodies detected the transfected protein. B, live labeling with the same antibodies was
present only with anti-tGFP antibodies, suggesting that the N-terminal epitopes are not exposed on the external side of the plasma membrane. Scale bar 	 20
m. The different accessibility of PRRT2 epitopes to the antibodies used in each experiment is shown in the left panels. When cells are permeabilized, anti-PRRT2
antibodies can enter the cells and recognize intracellular N-terminal epitopes. Under live labeling condition, the intact plasma membrane blocks their
accessibility to N-terminal epitopes.
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ments, we generated a PRRT2 mutant by inserting a stop codon
after valine 344 in the PRRT2-HA construct. This PRRT2
mutant, lacking the C-terminal lysine (and the C-terminal HA
tag), is predicted not to bind biotin at the C terminus of the
protein (PRRT2C, Fig. 4A).
COS7 cells were transfected with either wild-type
PRRT2-HA or PRRT2C, incubated with the biotin reagent,
precipitated with NeutrAvidin beads, and analyzed by Western
blotting. PRRT2 was present in the biotinylated fraction, sug-
gesting that at least one domain of the protein was extracellular
and bound biotin. Interestingly, the mutation of the C-terminal
lysine virtually abolished biotinylation of the protein, suggest-
ing that this residue was indeed responsible for the surface
labeling (Fig. 4B, top). The residual faint band that was still
visible in the bound fraction with the C-terminal mutant of
PRRT2 represents nonspecific binding of the protein to the
FIGURE 3. Ultrastructural localization of the C and N termini of PRRT2 expressed in COS7 cells. A and B, representative micrographs, obtained with the
pre-embedding (A) or post-embedding (B) technique, of COS7 cells transfected with either C-terminal PRRT2-HA (A1 and B1) or N-terminal HA-PRRT2 (A2 and
B2) and immunogold-labeled with anti-HA antibodies. Non-transfected cells (CTRL, A3 and B3) were also processed as negative controls. A1b and A2b, ImageJ
masks of A1 and A2, highlighting the plasma membrane (blue) and the gold particles (red) mapping the N and C termini of PRRT2. B1b and B2b, ImageJ masks
of B1 and B2, highlighting the plasma membrane (blue) and the gold particles (red). A4 and B4, additional images of plasma membrane domains of transfected
COS7 cells mapping the C-terminal (top panels) or N-terminal PRRT2 (bottom panels). C, representative EM micrographs of PRRT2-expressing COS7 cells
obtained with the Tokuyasu cryo-immunogold technique. Cells were co-transfected with N-terminally labeled GFP-PRRT2 and C-terminally labeled PRRT2-HA
or left untransfected as a negative control. Representative cryosections labeled with anti-GFP antibodies coupled to 10-nm nanogold particles (left panel) and
anti-HA antibodies coupled with 6-nm gold particles (center panel and inset) are shown. Additional images visualizing the location of GFP (C1 and C2) and HA
(C3 and C4) immunoreactivities are also shown. N, nucleus; ER, endoplasmic reticulum; M, mitochondrion. Scale bars 	 100 nm. D, quantification of the
percentage of gold particles located inside (cytosolic) or outside of (external) the plasma membrane from pre- and post-embedding specimens. Error bars
represent the mean 
 S.E. (n 	 46 images from 3 independent experiments) for the C-terminal (black) and N-terminal (red) labeling of PRRT2, respectively. ***,
p  0.01; Student’s t test. E, the occurrence of gold particles decorating the C terminus (C-terminal HA) or the N terminus (N-terminal GFP) of PRRT2 calculated
from the cryo-immunolabeled sections shown in C. The position of the gold particles was quantified with respect to both the plasma membrane (cytosolic/
external) and the membrane of intracellular organelles (cytosolic/lumenal).
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beads because it was still present when the biotin reagent was
omitted (Fig. 4C). Quantification of the immunoblots con-
firmed the strong decrease in specific biotin labeling of the
PRRT2C isoform versus the WT (Fig. 4D).
To confirm that the N-terminal lysines are not involved in
biotinylation, we generated an additional PRRT2 mutant lack-
ing the N-terminal domain (PRRT2N, Fig. 4E). The construct
encodes PRRT2 residues from Gly-267 to Lys-346 (the very
same sequence modeled by MD simulations, see Fig. 5) plus the
HA3 tag, and lacks almost completely the N-terminal domain
together with the nine N-terminal lysines. Moreover, we addi-
tionally mutated Lys-270 into an arginine (similarly charged
residue but not prone to biotinylation) so that the PRRT2N
mutant retained only two lysines: Lys-320 between the two
putative transmembrane domains and the C-terminal Lys-346.
Despite the large deletion, the PRRT2N mutant was exposed
correctly to the plasma membrane, as shown by live labeling
with anti HA antibodies (Fig. 4E). Biotinylation assays of
FIGURE 4. PRRT2 is surface-biotinylated at the C-terminal domain. A, biotin labeling of the C-terminal lysine residue of PRRT2 and the lack of labeling of the
deletion mutant PRRT2C lacking the C-terminal domain and the HA tag. B, Western blotting analyses probed with anti-PRRT2 antibodies showed biotin
labeling of wild-type PRRT2-HA and a strong decrease in biotinylation of PRRT2C. Both isoforms were expressed equally in the cells (input). Their presence in
the unbound fraction corresponds to the intracellular pool of the overexpressed protein. Na/K ATPase and actin were used as positive and negative controls
of surface biotinylation, respectively. C, representative control experiment in which biotin was omitted. The faint PRRT2 bands represent a low degree of
nonspecific binding to the NeutrAvidin beads. D, immunoblots were quantified by densitometric analysis of the fluorograms obtained in the linear range of the
emulsion response. The specific biotin labeling of PRRT2 was calculated as [total biotinylation/input  nonspecific biotinylation/input] and is expressed in
arbitrary units (a. u.). Specific biotinylation, shown as mean 
 S.E. of three independent experiments, is decreased significantly in PRRT2C compared with WT
PRRT2-HA. **, p  0.01; Student’s t test for paired samples. E, the PRRT2 mutant lacking the N-terminal domain (PRRT2N) and its plasma membrane expression
by live labeling with anti HA antibodies. F and G, representative Western blotting analysis probed with anti-HA antibodies (F) and quantification of the specific
biotinylation (G, mean 
 S.E., n 	 3) showing that both WT PRRT2-HA and PRRT2N are biotinylated specifically to approximately the same extent.
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PRRT2N showed that this mutant was biotinylated effectively
to the same extent as PRRT2-HA, confirming that the lysine
residue responsible for PRRT2 biotinylation is Lys-346 and that
the N-terminal lysines are not involved in the reaction (Fig. 4, F
and G).
To check the reliability of surface biotinylation and the integ-
rity of the plasma membrane, we analyzed intracellular proteins
such as actin. Indeed, actin was totally absent from the biotiny-
lated fraction and was only present in the unbound fraction
(Fig. 4, B–E, and F, bottom panel). Moreover, a positive control
of biotinylation, i.e. the transmembrane protein Na/K-
ATPase, was enriched, as expected, in the biotinylated fraction
(Fig. 4 B–E, and F, center panel). Both WT and mutant PRRT2
isoforms were also present in the NeutrAvidin-unbound frac-
tion, representing an intracellular pool of the protein being pro-
cessed by the secretory machinery of the cell. These results
confirm, with a fully independent approach, the extracellular
exposure of the C terminus and the intracellular localization of
the Lys-rich N-terminal region of PRRT2.
Structural Modeling and MD Simulations of PRRT2
Topology—All-atom structural models of the PRRT2 protein
transmembrane domain, including residues Gly-261 to Lys-340
of human PRRT2, were generated using the Rosetta online soft-
ware (35). Among the obtained models, the best-scoring one
(Fig. 5A) has good structural quality assessment values, a nor-
malized Qmean of 0.49, and a Z score of 1.85 (note that mem-
brane proteins usually get lower Z scores than soluble proteins
(34)). In the model, charged residues are located in two distant
regions of the chain, interspersed by mostly hydrophobic
amino acids. This clearly identifies putative solvent-accessible
and membrane-spanning regions of the chain. The most strik-
ing feature of the structure is the helix-loop-helix motif dis-
played by the TM1 domain (Ile-269 to Ala-289), with two 
helices extending from residues Ile-269 to Pro-279 and from
residues Ile-285 to Ala-289, linked by a short hinge comprising
residues Met-280 to Asn-284. This particular conformation
keeps both edges of the TM1 segment in the cytoplasm, imply-
ing that the model is consistent with our hypothesis that the full
PRRT2 protein N-terminal is in the cytoplasmic region. Inter-
estingly, the hinge occurs in the proximity of two proline resi-
dues (Pro-279 and Pro-282). The region Tyr-290 to Ser-317,
connecting TM1 to TM2 and referred to previously as the cyto-
plasmic loop, is indeed on the same side of the N-terminal and,
therefore, also in the cytoplasm, although it shows some degree
of secondary structure.
To further validate and refine the PRRT2 transmembrane
segment model, we performed all-atom MD simulations of this
protein portion in a water-membrane model environment
(POPC lipids). To insert the protein in the membrane, we based
ourselves on the location of hydrophobic and charged amino
acids, taking care that most of the charged residues were
exposed to the solvent and that the hydrophobic ones were
within the membrane. We performed two independent simu-
lations, one lasting 20 ns and one 50 ns, starting from two
slightly different protein-membrane conformations. A snap-
shot of the simulated protein and membrane system at the end
of the 20-ns trajectory is shown in Fig. 5B, where water and
some lipid molecules were removed for clarity. In the figure,
FIGURE 5. Molecular dynamics simulations of PRRT2 topology. A, predicted model of the PRRT2 protein transmembrane domains (residues 261–340). The
protein backbone is shown as a schematic, whereas charged residues are shown as sticks and colored according to their type (blue, basic; red, acidic). Proline
residues are also shown as sticks. Dashed lines indicate putative membrane limits. B, snapshot of the protein and membrane system at the end of the 20-ns MD
trajectory. Water molecules and some lipids were removed for clarity. The residues mutated in the PRRT2 sequence (6) are shown as spheres and colored
according to their type (blue/red, charged; green, polar; white, hydrophobic). C, root mean square displacement (RMSD) of the protein structure with respect to
the starting conformation along the 20-ns (blue) and 50-ns (black) MD trajectories. D, fraction of native contacts along the 20-ns (blue) and 50-ns (black) MD
trajectories.
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residues belonging to a list of PRRT2 point mutations (6) are
shown as spheres colored according to their type (blue, basic;
red, acidic; green, polar; white, hydrophobic). The structure was
overall stable along both simulations, showing a root mean
square displacement from the starting conformation that
reached plateaus around 1.5 and 3 Å for the 20- and 50-ns
trajectories, respectively (Fig. 5C). The fraction of native con-
tacts was stationary along both simulated trajectories (Fig. 5D),
again revealing a stable structure.
The Intracellular Proline-rich N-terminal Domain Binds SH3
Domains—Several minimal Pro-X-X-Pro consensus sequences
for Src homology 3 (SH3) domain binding are present in the
primary structure of the N-terminal domain of PRRT2 (pro-
line-rich domain; residues 133–136, 157–160, 206 –209, and
242–245 in the N-terminal domain of mouse PRRT2). After we
established that this domain is exposed to the interior of the
cell, we preliminarily assessed whether it is able to bind SH3
domains from an array of proteins involved in signal transduc-
tion and/or synaptic vesicle cycling. Therefore, we asked
whether PRRT2 could be specifically affinity-purified from an
extract of crude synaptosomal fractions (P2) obtained from rat
forebrain by the SH3 domains of Crk, c-Src, Amphiphysin II,
Intersectin 1 SH3-A, and Endophilin 1, expressed as fusion pro-
teins with GST, using GST alone as nonspecific binding con-
trol. PRRT2 was pulled down to various extents by the individ-
ual SH3 domains. Notably, the Endophilin 1 and Intersectin 1
SH3-A domain displayed the highest interactions (Fig. 6, A and
B). As an internal control, all SH3 domains analyzed also bound
dynamin I to the same extent, as described previously (27). To
verify whether these interactions with isolated recombinant
SH3 domains could translate into an interaction with the holo-
protein, we performed co-immunoprecipitation experiments
with Endophilin 1 and Intersectin 1, two nerve terminal pro-
teins implicated in the recycling of synaptic vesicles whose SH3
domain showed strong PRRT2 binding in the pulldown assay.
Interestingly, anti-Intersectin 1 antibodies did co-immunopre-
cipitate PRRT2, whereas anti-Endophilin 1 antibodies failed to
do so (Fig. 6C).
Discussion
Understanding the topology of membrane proteins is an
important step for the comprehension of the molecular mech-
anisms of protein function. PRRT2 is a protein with a putative
role at the synapse that is responsible, when mutated, for vari-
ous paroxysmal disorders of infancy. It is therefore of great
importance to obtain clues regarding its function to understand
the pathogenesis of these diseases. PRRT2 belongs to the family
of Dispanin, whose putative topology has been predicted to
consist of two transmembrane domains connected by a short
intracellular loop and two extracellular N- and C-terminal
domains. To unambiguously define the function of PRRT2 at
the synapse, it is important to confirm the exact orientation of
its N and C termini with respect to the plasma membrane
to obtain clues regarding its possible key interactors and
functions.
The experiments presented in this paper demonstrate
unequivocally a novel PRRT2 topology by several experimental
approaches. Live-cell labeling experiments, performed with
FIGURE 6. Affinity purification of PRRT2 by SH3 domains from extracts of
brain synaptosomes A, pulldown assay. Affinity resins were prepared by
coupling the SH3 domains of Crk, c-Src, Amphiphysin II (Amphi II), Intersectin
1 SH3-A (Itsn1-A), or Endophilin 1 (Endo1) or GST alone to glutathione-Sephar-
ose. Columns were loaded with a Triton X-100 extract of crude synaptosomal
fraction (P2) from rat forebrain. Bound proteins were eluted with SDS, sepa-
rated by SDS-PAGE, and analyzed by immunoblotting with anti-PRRT2- or
anti-dynamin (DYN)-specific antibodies. Center panel, the elution patterns of
PRRT2. The immunoreactivity of dynamin I (top panel) is shown for compari-
son. Bottom panel, recovery of the GST-tagged SH3 domains after Coomassie
staining of the gels. B, quantification of the pulldown. Immunoblots were
analyzed by densitometry of the fluorograms obtained in the linear range of
the emulsion response to quantify band immunoreactivity. The amount of
PRRT2 associated with the respective SH3 domains was calculated as the ratio
of specific PRRT2-SH3 domain binding (immunoreactivity of the PRRT2 SH3
GST domain  immunoreactivity of PRRT2 GST) with the unspecific binding
(immunoreactivity of PRRT2 GST) and expressed as mean 
 S.E. (n 	 5). C,
co-immunoprecipitation. Detergent extracts of mouse brain were immuno-
precipitated with anti-intersectin 1 monoclonal antibodies, anti-endophilin-1
monoclonal antibodies, or mouse IgG, as indicated (IP). After electrophoretic
separation of the immunocomplexes and Western blotting, membranes were
probed with antibodies against Itsn1 and Endo1 to test the efficiency of the
immunoprecipitation (bottom blots) and with anti-PRRT2 antibodies (top
blots).
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various sets of PRRT2 constructs, showed identical results. The
use of the same anti-HA antibodies to target the N and C ter-
mini of PRRT2 excludes possible artifacts due to antibody mal-
function under live labeling conditions. When cells were not
permeabilized, the N-terminal epitopes were not accessible by
antibodies that, instead, recognized the C-terminal epitopes,
indicating that the C terminus is, as predicted, exposed at the
external surface of the cell, whereas the N terminus is inside of
the cell, at variance with the predicted topology.
These results were confirmed by immunoelectron micros-
copy, which showed unambiguously the presence of C terminus
immunoreactivity on the external leaflet of the plasma mem-
brane, whereas N terminus immunoreactivity was confined
inside the cell. The novel topology was also confirmed indepen-
dently by surface biotinylation. Although the mutation of the
single C-terminal lysine virtually abolished biotin labeling, the
lack of 10 N-terminal lysines did not influence the reaction,
suggesting that these residues are located intracellularly.
The new orientation of the N-terminal domain toward the
intracellular space leads to the consequence that only the sec-
ond C-terminal hydrophobic segment spans the plasma mem-
brane and protrudes into the extracellular space with the short
C-terminal domain. Therefore, the first N-terminal hydropho-
bic segment does not cross the membrane and remains puta-
tively associated with its cytoplasmic leaflet. The structure of
the C-terminal region was modeled computationally and
refined further by MD simulations in a water-membrane envi-
ronment. Through this advanced bioinformatics analysis, it was
possible to ascertain that the  helix of TM1 flexes in correspon-
dence with a five-amino acid hinge that includes two proline
residues and forms a helix-loop-helix structure. Although helix
destabilization by prolines is most frequently observed in solu-
ble proteins, proline-induced distortions are also present in
structures of transmembrane chains, where they are supposed
to facilitate helical packing motifs (42). Therefore, both edges of
the TM1  helix protrude in the cytoplasm, where they are
connected to the N-terminal domain and the cytoplasmic loop.
Taken together, these results define an alternative Ncyt/Cexo
PRRT2 topology consistent with a type II transmembrane pro-
tein in which only the second hydrophobic segment completely
spans the plasma membrane, the first hydrophobic segment is
associated with the internal half of the plasma membrane via a
helix-loop-helix structure, and the N terminus is intracellular.
PRRT2 is not the only member of the dispanin family to show a
different topology with respect to the originally predicted one.
The recently clarified topology of interferon-induced trans-
membrane proteins, constituting a subfamily of the dispanins,
supports the novel PRRT2 topology demonstrated here. Recent
reports have demonstrated that two members of this family,
interferon-inducible transmembrane proteins 1 (28) and 3 (43),
display a PRRT2-like topology, with the N terminus oriented
toward the cytosolic compartment and the C terminus
extracellular.
The novel PRRT2 topology demonstrated in this paper has
important implications for PPRT2 function. In fact, the intra-
cellular location of the N-terminal domain, which accounts for
80% of the primary structure of the protein, opens the possibil-
ity of novel interactions with intracellular proteins involved in
synaptic function and leads to the formulation of completely
different functional hypotheses for PRRT2. Interestingly, by
means of pulldown assays, we showed binding of PRRT2 with a
few SH3 domains belonging to synaptic and regulatory proteins
involved in exo/endocytosis of synaptic vesicles or in signal
transduction, including those of Endophilin 1 and Intersectin 1,
which are key players in clathrin-mediated endocytosis at nerve
terminals (44). Notably, co-immunoprecipitation assays con-
firmed an interaction of PRRT2 with Intersectin 1 but not with
Endophilin 1. Although this discrepancy may result from dif-
ferences in binding to an isolated SH3 domain or to the entire
protein, the confirmed interaction with Intersectin 1 is addi-
tional proof of the intracellular localization of the PRRT2 N
terminus and suggests a potential functional role of the protein
in the regulation of vesicle trafficking and endocytosis.
The novel Ncyt/Cexo topology of PRRT2 makes the demon-
strated interaction of PRRT2 with the SNARE protein
SNAP-25 more plausible. Although, according to the originally
predicted PRRT2 topology, the interaction was confined to the
single short cytosolic loop, the new PRRT2 topology with the
large PRRT2 N-terminal domain inside the cell allows multiple
interactions sites not only for SNAP-25 but also for other mem-
bers of the presynaptic interactome. Most of the proteins play-
ing key roles in the final priming/fusion steps of release, includ-
ing synaptotagmins, vesicle-associated membrane protein,
syntaxin, and SNAP-25 have large interacting cytosolic
domains, and, notably, PRRT2, vesicle-associated membrane
protein 2, and syntaxin are all type II transmembrane proteins
with a C-terminal anchor. The novel topology of PRRT2 will
give breathing space to the search for new intracellular interac-
tors and will contribute to clarify the role of this important
protein in synaptic transmission as well as the pathogenic
mechanisms by which its mutations lead to neurological
manifestations.
Author Contributions—P. R. and B. S. performed the cell and molec-
ular biology studies, including immunocytochemistry and surface
biotinylation experiments. E. C. performed and analyzed the immu-
noelectron microscopy experiments. L. M. performed structure
modeling studies and MD simulations. F. O. and A. M. performed
the pulldown assays with SH3 domains. A. C., F. V., and F. B.
designed and supervised the research and analyzed the data. F. B. and
A. C. wrote the paper and supported the study.
Acknowledgments—We thank Diego Moruzzo (Department of Neu-
roscience and Brain Technologies, Istituto Italiano di Tecnologia,
Genova, Italy) for preparation of the HA constructs and Romina Ines
Cervigni (San Raffaele Scientific Institute, Milan, Italy) for prepara-
tion of the GFP constructs. We also thank Silvia Casagrande (Depart-
ment of Experimental Medicine, University of Genova, Italy) for tech-
nical assistance and acknowledge the IIT Platform “CompuNet” for
CPU time.
References
1. Méneret, A., Gaudebout, C., Riant, F., Vidailhet, M., Depienne, C., and
Roze, E. (2013) PRRT2 mutations and paroxysmal disorders. Eur. J. Neu-
rol. 20, 872– 878
2. Heron, S. E., and Dibbens, L. M. (2013) Role of PRRT2 in common parox-
ysmal neurological disorders: a gene with remarkable pleiotropy. J. Med.
A Novel Topology for PRRT2 Supports Intracellular Functions
MARCH 18, 2016 • VOLUME 291 • NUMBER 12 JOURNAL OF BIOLOGICAL CHEMISTRY 6121
 at B













3. Becker, F., Schubert, J., Striano, P., Anttonen, A. K., Liukkonen, E., Gaily,
E., Gerloff, C., Müller, S., Heußinger, N., Kellinghaus, C., Robbiano, A.,
Polvi, A., Zittel, S., von Oertzen, T. J., Rostasy, K., Schöls, L., Warner, T.,
Münchau, A., Lehesjoki, A. E., Zara, F., Lerche, H., and Weber, Y. G. (2013)
PRRT2-related disorders: further PKD and ICCA cases and review of the
literature. J. Neurol. 260, 1234 –1244
4. Guerrini, R., and Mink, J. W. (2012) Paroxysmal disorders associated with
PRRT2 mutations shake up expectations on ion channel genes. Neurology
79, 2086 –2088
5. Wood, H. (2012) Genetics: Expanding the spectrum of neurological dis-
orders associated with PRRT2 mutations. Nat. Rev. Neurol. 8, 657
6. Lee, H. Y., Huang, Y., Bruneau, N., Roll, P., Roberson, E. D., Hermann, M.,
Quinn, E., Maas, J., Edwards, R., Ashizawa, T., Baykan, B., Bhatia, K., Bress-
man, S., Bruno, M. K., Brunt E. R., Caraballo, R., Echenne, B., Fejerman, N.,
Frucht, S., Gurnett, C. A., Hirsch, E., Houlden, H., Jankovic, J., Lee, W. L.,
Lynch, D. R., Mohammed, S., Müller, U., Nespeca, M. P., Renner, D.,
Rochette, J., Rudolf, G., Saiki, S., Soong, B. W., Swoboda, K. J., Tucker, S.,
Wood, N., Hanna, M., Bowcock, A. M., Szepetowski, P., Fu, Y. H., and
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